Be at the forefront of the Bispecific space as it goes head to head with cell therapy to transform oncology. Among numerous innovations in cancer immunotherapy, Bispecific antibody treatments have never been more promising with continuous clinical updates and approvals over the last year, including the huge waves seen in multiple myeloma and lymphoma treatment.

The World Bispecific Summit returns for its 14th year with an enriched program boasting comprehensive coverage of all the key discovery, pre-clinical and clinical challenges including design, clinical, regulatory and combination strategies. Led by the industry's brightest minds from the likes of Sanofi, Regeneron, the FDA, Alligator Biosciences and Amgen, it's the perfect platform to celebrate wins, work through challenges and establish connections with the leading pharma, biotech and academic KOLs.  Deep dive into novel target selection, immune cell modulators, target selection and pre-clinical/clinical readouts and gain holistic insight on the current state-of-play in the bispecific landscape to supercharge your own pipeline from discovery through to IND approval.

Read on go.evvnt.com

Continue reading at bispecific.com

Oncology

Facebook Share

Twitter Share

Linkedin Share

Email Share